Target intelligence / Profile preview

Niban apoptosis regulator 2 (NIBAN2)

Target
NIBAN2
Molecular classification
Apoptosis regulator, Transcription coactivator, Signal transduction modulator (AKT substrate)
01

Overview

Niban apoptosis regulator 2 (NIBAN2), also known as FAM129B or MINERVA, is a stress-responsive protein that regulates apoptosis primarily via modulation of the p53 degradation pathway. Upon stress (such as ultraviolet irradiation), NIBAN2 is phosphorylated by AKT at serine 602, which enhances its binding to nucleophosmin (NPM). This disrupts NPM's stabilizing effect on p53, promoting MDM2-mediated p53 degradation and resulting in a survival advantage to cells under genotoxic stress. NIBAN2 is notably overexpressed in human cancer cells and may play a role in cancer progression through antiapoptotic mechanisms and, in melanoma, by promoting cell invasion. Its functions position it as a potential therapeutic target or biomarker for certain malignancies, though direct drug targeting is not yet established in clinical settings

Other names
Protein Niban 2C9orf88FAM129BMINERVADKFZP434H0820FLJ13518FLJ22151FLJ22298bA356B19.6Meg-3Melanoma invasion by ERKNiban-like protein 1Protein FAM129BMEG-3OC58family with sequence similarity 129 member B
02

Mechanism of action

AKT-dependent phosphorylation modulates NIBAN2 function. Inhibition of AKT prevents NIBAN2 phosphorylation and its antiapoptotic effects. Indirect targeting through AKT/PI3K pathway affects NIBAN2-mediated survival.

03

Biological functions

Negative regulation of apoptosisRegulation of p53 stability and degradationCell survival in response to stressPromotion of cancer cell invasion (notably melanoma)Cadherin bindingRegulation of nucleobase-containing compound metabolic process
04

Disease associations

Cancer (e.g. melanoma, glioblastoma, lung cancer)Other roles in cell stress responses possibly involving tumorigenesis
05

Safety considerations

Modulating NIBAN2 could disrupt cellular apoptotic balance, potentially promoting tumorigenesis or unwanted cell survival
06

Interacting drugs

AKT inhibitors (e.g., MK-2206, AKT inhibitor IV; used in mechanistic studies but not clinical targeting of NIBAN2 directly)
07

Biomarkers

Overexpression of NIBAN2/FAM129B is observed in various cancers and may indicate tumor cell survival/apoptosis resistance

Beyond the preview

Go deeper on Niban apoptosis regulator 2 (NIBAN2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Niban apoptosis regulator 2 (NIBAN2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call